ZS801 for adults with severe hemophilia B
Part of Blood & lymphatic, Genetic & congenital clinical trials.
This trial studies ZS801, a gene therapy, in adults with hemophilia B who have very low natural FIX (a clotting protein) and frequent bleeding or joint problems. It aims to see how well it works and whether it is safe, especially by monitoring blood counts, infections, and immune responses.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a man age 18 to 65
- You have confirmed hemophilia B with your own FIX level at 2% or less
- You must have used FIX treatment for at least 100 prior exposure days
- In the past year, you had at least 3 bleeding events or ongoing joint bleeding needing FIX treatment
- You must be able to use reliable birth-control measures and not donate sperm until 52 weeks after the infusion
- You must be willing to follow the study plan and provide blood/other samples
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 1/2 study tests ZS801, a gene-related treatment, to see how safe it is and whether it helps prevent bleeding in adults with hemophilia B. You may be considered if you’ve had frequent bleeds or joint problems and meet several lab and health requirements.
This Phase 1 study tests a one-time gene therapy treatment (BBM-H901) for boys ages 12 to 18 with hemophilia B. It aims to see if the treatment is safe and can help the body make more clotting factor over time.
This trial tests a one-time (or limited) gene therapy meant to help the body make more factor IX (FIX), which can reduce bleeding in people with hemophilia B. You may be able to qualify if you have significant bleeding history, no factor IX “blockers” (inhibitors), and can follow strict safety and pregnancy-prevention rules.
This trial tests a single dose of ANB-002, an experimental therapy for hemophilia B. It aims to see if the drug is safe and effective for people with severe hemophilia B who have been treated with factor IX before and do not have inhibitors.
This trial tests a new gene therapy (REGV131-LNP1265) that aims to let your body produce its own factor IX, reducing or stopping the need for regular infusions. It is for children and adults with severe hemophilia B who are already using factor IX replacement therapy.
This study tests a new gene therapy called ANB-002 for men with severe hemophilia B (factor IX levels at or below 2%). The goal is to see if it's safe and how well it might help your blood clot normally.
Hear when a new Hemophilia B trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.